Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452374 | 0.91 | PDE4B (0.70) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3451607 | 0.89 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL4669096 | 0.85 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL3450814 | 0.84 | PDE4B (0.77) | PDE4BPDE4APDE4CPDE4DTSHR | |
| SCHEMBL4670367 | 0.82 | PDE4B (0.73) | PDE4BPDE4APDE4CPDE4DTSHR | |
| SCHEMBL3451767 | 0.82 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL4672854 | 0.81 | PDE4B (0.84) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL3453010 | 0.80 | PDE4B (0.73) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3453181 | 0.78 | PDE4B (0.78) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL3451228 | 0.76 | PDE4B (0.64) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716133-B1 | 2-(PIPERIDIN-4-YL)-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-03-26 | — | — | EP | claimed |
| US-7820669-B2 | 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20090131448-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7494990-B2 | 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| EP-1716133-B1 | 2-(PIPERIDIN-4-YL)-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20070179146-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | ATLANTA PHARMA AG (DE) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131448-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20070179146-A1 | 2-(Piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4A 1/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.